On Tuesday, 18 November, the European Commission adopted a decision concerning the market authorisation for brensocatib, a new active substance intended to treat chronic progressive non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 and older.
This rare disease affects between 400,000 and three million people in Europe and is characterised by damaged airways and severe pulmonary dysfunction. It often causes chronic cough and airflow obstruction.
Bronchiectasis is caused by...